SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $755,658 | -26.1% | 16,071 | -34.0% | 0.01% | -16.7% |
Q1 2023 | $1,021,852 | +31.4% | 24,353 | +19.5% | 0.01% | +20.0% |
Q4 2022 | $777,446 | -31.1% | 20,384 | -29.3% | 0.01% | -16.7% |
Q3 2022 | $1,129,000 | -56.8% | 28,834 | -64.4% | 0.01% | -62.5% |
Q2 2022 | $2,614,000 | +28.5% | 80,923 | +31.6% | 0.02% | -5.9% |
Q1 2022 | $2,035,000 | -52.7% | 61,470 | -39.3% | 0.02% | -58.5% |
Q4 2021 | $4,306,000 | -13.5% | 101,230 | -9.9% | 0.04% | -34.9% |
Q3 2021 | $4,979,000 | +171.0% | 112,376 | +247.5% | 0.06% | +200.0% |
Q2 2021 | $1,837,000 | +5.6% | 32,340 | +39.1% | 0.02% | -4.5% |
Q1 2021 | $1,740,000 | -31.3% | 23,250 | -43.9% | 0.02% | -42.1% |
Q3 2020 | $2,534,000 | +58.4% | 41,459 | +7.7% | 0.04% | +35.7% |
Q2 2020 | $1,600,000 | -30.3% | 38,479 | -51.9% | 0.03% | -54.8% |
Q1 2020 | $2,297,000 | -56.2% | 79,986 | +10.1% | 0.06% | -35.4% |
Q4 2019 | $5,243,000 | +1020.3% | 72,624 | +2075.7% | 0.10% | +966.7% |
Q3 2019 | $468,000 | -8.2% | 3,338 | +19.9% | 0.01% | 0.0% |
Q2 2019 | $510,000 | -57.1% | 2,785 | -62.8% | 0.01% | -76.9% |
Q1 2019 | $1,190,000 | +107.3% | 7,479 | +24.7% | 0.04% | +44.4% |
Q4 2018 | $574,000 | -65.3% | 5,996 | -48.9% | 0.03% | -70.0% |
Q3 2018 | $1,656,000 | -86.1% | 11,727 | -84.6% | 0.09% | -84.9% |
Q2 2018 | $11,913,000 | +20439.7% | 76,110 | +21645.7% | 0.60% | +19833.3% |
Q4 2017 | $58,000 | -12.1% | 350 | -66.7% | 0.00% | -25.0% |
Q3 2017 | $66,000 | -73.0% | 1,052 | -65.6% | 0.00% | -75.0% |
Q2 2017 | $244,000 | +115.9% | 3,058 | +91.8% | 0.02% | +100.0% |
Q1 2017 | $113,000 | -8.1% | 1,594 | -34.1% | 0.01% | -20.0% |
Q4 2016 | $123,000 | -19.1% | 2,418 | -26.9% | 0.01% | 0.0% |
Q3 2016 | $152,000 | +15100.0% | 3,306 | +7246.7% | 0.01% | – |
Q2 2016 | $1,000 | -99.9% | 45 | -99.8% | 0.00% | -100.0% |
Q1 2016 | $802,000 | +206.1% | 25,023 | +304.1% | 0.05% | +253.8% |
Q3 2015 | $262,000 | +20.7% | 6,192 | -10.2% | 0.01% | 0.0% |
Q3 2014 | $217,000 | – | 6,895 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |